|| Checking for direct PDF access through Ovid
Enalapril deserves wider use in patients with symptomatic heart failure. In these patients, enalapril reduces mortality and hospitalisation rates, and produces modest improvements in quality of life. Moreover, pharmacoeconomic models have predicted that the costs of administering the drug are more than offset by cost savings resulting from reduced hospitalisation.In addition, enalapril does not have deleterious effects on the quality of life of patients with asymptomatic left ventricular dysfunction or mild to moderate hypertension. Thus, quality-of-life data support the use of enalapril in these indications also.These findings may also apply to other ACE inhibitors, since few differences have become apparent between members of this drug class in clinical trials.